Monoclonal antibodies targeting programmed cell death protein- or ligand-1 (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have altered the treatment landscape of advanced or metastatic non-small-cell lung cancer (NSCLC) as well as extensive-stage small-cell lung cancer (SCLC) and represent the standard of care for the majority of cases [3]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.